Coagulation and Natural Anticoagulants » Coagulation Factors and Inhibitors

Abstract Number: PB0057

Ex vivo Evaluation of the Effect of Plasma-derived Factor VIII/von Willebrand Factor in Patients with Severe Hemophilia A on Prophylaxis with Emicizumab by ROTEM

E. Monzón Manzano¹, E. Arias-Salgado¹, P. Acuña¹, M.-I. Bravo², A. Raventos², A. Perez², M.T. Álvarez Román¹, N. Butta¹, M. Costa², T. Willis³, V. Jimenez-Yuste^1,4

Abstract Number: OC 05.3

A Novel Prediction Platform to Enhance the Design of Therapeutic SERPINs

W. Sanrattana¹, T. Sefiane², S. Smits¹, M. Fens³, D. Monroe⁴, P. Lenting², C. Maas¹, S. de Maat¹

Abstract Number: OC 27.4

A Unique Loop Structure in the A2-domain of Pseudonaja textilis Factor Va Prevents Activated Protein C-catalyzed A2-domain Dissociation

M. Schreuder^1,2, X. Liu³, K.L. Cheung¹, P.H. Reitsma^1,4, G.A.F. Nicolaes³, M.H.A. Bos¹

Abstract Number: LB 01.2

Abelacimab for Prevention of Venous Thromboembolism

P. Verhamme¹, A. Yi², A. Segers³, J. Salter², D. Bloomfield², H. Buller⁴, G. Raskob⁵, J. Weitz⁶

Abstract Number: PB0072

Analysis of Coagulation Factors in Fresh-frozen Plasma

M. Pikta^1,2, T. Szanto³, R. Reimal⁴, P. Muliin⁴, H. König⁵, G. Blinova⁵, V. Banys⁶

Abstract Number: PB0058

Are Direct Oral Anti-Xa Inhibitors Absorbed in Cancer Patients after Gastrectomy? A Case Series

H.C. Puhr¹, A. Ilhan-Mutlu¹, P. Quehenberger¹, P.A. Kyrle¹, S. Eichinger¹, L. Eischer¹

Abstract Number: PB0051

Combining Heparin with a FX/FXa Aptamer to Reduce Thrombin Generation in Models of Cardiopulmonary Bypass and COVID-19 Associated Coagulopathy

C.V. Chabata^1,2, J.W. Frederiksen¹, L.B. Olson^2,3, I.A. Naqvi⁴, B.A. Sullenger¹

Abstract Number: PB0047

Comparing the Real-world and Clinical Trial Bleeding Rates Associated with Anticoagulation Treatment for Atrial Fibrillation

R. Buderi¹, A. Yi², P. Allen¹, T. Bebi¹, C. Vigna¹, R. Jain¹, A. Majumdar¹, D. Bloomfield², J. Salter², D. Freedholm², A. Galaznik¹

Abstract Number: PB0045

D-dimer and the Risk of Diabetes: The REasons for Geographic and Racial Differences in Stroke (REGARDS)

D. Kamin Mukaz¹, D.L. Long², T.B. Plante¹, S.E. Judd², L.A. McClure³, A.S. Wolberg⁴, A.P. Carson², B. Guo², M. Cushman¹

Abstract Number: OC 43.1

Deep Mutational Scan of the VWF C Domains to Define Mutations Associated with VWD

T. Sparring¹, K. Singh¹, H. Madarati¹, C. Kretz¹

Abstract Number: OC 14.3

Development of Monoclonal Antibodies that Protect FV/FVa from APC-mediated Inactivation for the Treatment of Bleeding

S. Quinn¹, F. Ayombil¹, R.M. Camire²

Abstract Number: OC 60.4

Discovery and in vitro Characterization of an Antibody Fragment (Fab) which Neutralizes Milvexian (BMS-986177/JNJ-70033093)

Y. Wu¹, L. Schneeweis¹, J. Pinckney², C. Terragni², S. Mai¹, Y. An¹, J. Gordon², A. Kozhich¹, A.K. Dilger¹, W.R. Ewing¹, P. Nandi¹, J.M. Luettgen¹

Abstract Number: PB0067

Evaluation and Performance Characteristics of the Automated Sysmex CN-6000 Haemostasis Analyzer

I. Martin-Toutain¹, M. Gaaloul¹, M. Berber¹, E. Bailly¹, J.-P. Delorme², Y. Bourti², C. Frere^1,3

Abstract Number: PB0052

Evaluation of a New Thromboplastin Reagent Containing Human Recombinant Tissue Factor for the Determination of Prothrombin Time Reagent: the (h)PT-Phen™ LRT

I. Martin-Toutain¹, M. Gaaloul¹, J.-P. Delorme², Y. Bourti², C. Frere^1,3

Abstract Number: OC 05.4

Evolutionary Adaptation of the Gamma-carboxyglutamic Acid Domain in Venom Factor X from the Australian Common Brown Snake

S. Cheng^1,2, G. Poenou^1,3, K.L. Cheung¹, M. Schreuder^1,4, M.H. Bos¹

Abstract Number: PB0044

Factor XIa Inhibitor Milvexian (BMS-986177/JNJ-70033093) Suppresses Plasma Clot Formation and Reduces Resistance to Fibrinolysis in vitro

L.A. Holle¹, J.M. Luettgen², A.S. Wolberg¹

Abstract Number: OC 05.2

Fluorescence Correlation Spectroscopy Provides New Insights into the Mechanism of Prothrombin Recognition by the Prothrombinase Complex

M. Chinnaraj¹, N. Pozzi¹, E. Di Cera¹

Abstract Number: PB0038

Generation of Anticoagulant RNA Aptamers Targeting Cofactors that Inhibit Clotting in Normal and COVID-19 Patient Samples

H. Yu¹, E. Soule¹, L. Olson¹, I. Naqvi¹, S. Kumar², S. Krishnaswamy², B. Sullenger¹

Abstract Number: PB0055

HemosIL Liquid Anti-Xa Apixaban Measurement in Patients with High Risk of Major Bleeding

J. Hammelburger¹, Z. Cao¹, C. Kung¹

Abstract Number: PO121

Hemostatic Defects Associated with IgA Monoclonal Gammopathy

M.C. Shen^1,2, C.-W. Huang¹, G.-M. Lai¹, Y.-H. Shih¹, C.-Y.L. Lin¹, H.-Y. Lin¹, S.-F. Kuo¹, J.-S. Lin¹